Patents by Inventor Peter Bugelski

Peter Bugelski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CXCL13 antagonists and their use for the treatment of inflammatory diseases
    Patent number: 8277809
    Abstract: Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNF? antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: October 2, 2012
    Assignee: Centocor, Inc.
    Inventors: Peter Bugelski, Anuk Das, Donald E. Griswold, Bailin Liang, Li Li, Robert T. Sarisky, Xiaozhou Shang
  • METHOD OF TREATING ERYTHROPOIETIN HYPORESPONSIVE ANEMIAS
    Publication number: 20100266591
    Abstract: The invention relates to methods of using compositions comprising EPO-mimetic peptides to treat anemia. The invention relates to methods of treating disorders characterized by the insufficient amounts of erythrocytes and hemoglobulin in the blood due to myelodysplastic syndrome (MDS) or by hemoglobinopathies, such as alpha- or beta-thalessemia or sickle cell disease.
    Type: Application
    Filed: November 24, 2008
    Publication date: October 21, 2010
    Inventors: Peter Bugelski, Renold Capocasale, Dorie Makropoulos, Ram Achuthanandam
  • CXCL13 Antagonists and Their Use for the Treatment of Inflammatory Diseases
    Publication number: 20090136512
    Abstract: Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNF? antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
    Type: Application
    Filed: March 31, 2008
    Publication date: May 28, 2009
    Inventors: Peter Bugelski, Deg Griswold, Bailin Liang, Robert T. Sarisky
  • CXCL13 Antagonists and Their Use for the Treatment of Inflammatory Diseases
    Publication number: 20080014201
    Abstract: Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNF? antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
    Type: Application
    Filed: April 20, 2007
    Publication date: January 17, 2008
    Inventors: Peter Bugelski, Anuk Das, Donald Griswold, Bailin Liang, Li Li, Robert Sarisky, Xiaozhou Shang
  • Methods for identifying the toxic/pathologic effect of environmental stimuli on gene transcription
    Publication number: 20030224407
    Abstract: Methods are disclosed for assessing the toxic or pathologic effects of a selected environmental stimulus or reagent on a mammalian cell by determining on a DNA grid a “fingerprint” hybridization pattern. The fingerprint pattern is characteristic of chemically or structurally diverse stimuli or reagents, which having a common adverse effect on gene transcription. A test compound is screened for a similar toxic effect by comparing its hybridization pattern on a similar grid to the fingerprint.
    Type: Application
    Filed: March 6, 2003
    Publication date: December 4, 2003
    Inventors: Timothy Bertram, Michael J. Browne, Peter Bugelski, Paul England, Ian Mitchell, David Gwyn Morgan, Andrew Rut